Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cardiff Oncology
Biotech
High dose of Cardiff's KRAS drug shows 64% ORR, sending stock up
Cardiff reported deeper tumor responses among the patients receiving the 30-mg dose of the biotech's drug compared to those receiving 20 mg.
Gabrielle Masson
Dec 10, 2024 4:05pm
Cardiff chief medical officer leaves in less than a year
Apr 13, 2022 10:39am
Pfizer invests $15M in Cardiff to bankroll Amgen KRAS challenger
Nov 18, 2021 10:30am
Cardiff reveals early data on challenger to Amgen's KRAS crown
Sep 9, 2021 10:40am
